Similarly, the EGFR T790M mutation did not reflect the treatment efficacy of anlotinib in 17 patients with advanced NSCLC (5.53 months vs 5.53 months, HR = 1.35, 95% CI 0.75–2.41, P = 0.253) (30). This evidence concerns the gene EGFR and non-small cell lung carcinoma.